Malignant neuroendocrine tumors (C7A) ICD-10-CM
The C7A code range covers malignant neuroendocrine tumors with 28 ICD-10-CM diagnosis codes. 23 of them are billable and valid for claim submission in fiscal year 2027, and the category headers group them but cannot themselves be billed.
Code Also
A "code also" note instructs that two codes may be required to fully describe a condition, but this note does not provide sequencing direction.
- any associated multiple endocrine neoplasia [MEN] syndromes E31.2
Use Additional Code
The “use additional code” indicates that a secondary code could be used to further specify the patient’s condition. This note is not mandatory and is only used if enough information is available to assign an additional code.
- code to identify any associated endocrine syndrome, such as:
- carcinoid syndrome E34.00
Type 2 Excludes
A type 2 excludes note represents "Not included here". An excludes2 note indicates that the condition excluded is not part of the condition represented by the code, but a patient may have both conditions at the same time. When an Excludes2 note appears under a code, it is acceptable to use both the code and the excluded code together, when appropriate.
Codes in the C7A Range 28 codes · 23 billable
- C7A Malignant neuroendocrine tumorsNon-billable
- C7A.0 Malignant carcinoid tumorsNon-billable
- C7A.00 Malignant carcinoid tumor of unspecified site
- C7A.01 Malignant carcinoid tumors of the small intestineNon-billable
- C7A.010 Malignant carcinoid tumor of the duodenum
- C7A.011 Malignant carcinoid tumor of the jejunum
- C7A.012 Malignant carcinoid tumor of the ileum
- C7A.019 Malignant carcinoid tumor of the small intestine, unspecified portion
- C7A.02 Malignant carcinoid tumors of the appendix, large intestine, and rectumNon-billable
- C7A.020 Malignant carcinoid tumor of the appendix
- C7A.021 Malignant carcinoid tumor of the cecum
- C7A.022 Malignant carcinoid tumor of the ascending colon
- C7A.023 Malignant carcinoid tumor of the transverse colon
- C7A.024 Malignant carcinoid tumor of the descending colon
- C7A.025 Malignant carcinoid tumor of the sigmoid colon
- C7A.026 Malignant carcinoid tumor of the rectum
- C7A.029 Malignant carcinoid tumor of the large intestine, unspecified portion
- C7A.09 Malignant carcinoid tumors of other sitesNon-billable
- C7A.090 Malignant carcinoid tumor of the bronchus and lung
- C7A.091 Malignant carcinoid tumor of the thymus
- C7A.092 Malignant carcinoid tumor of the stomach
- C7A.093 Malignant carcinoid tumor of the kidney
- C7A.094 Malignant carcinoid tumor of the foregut, unspecified
- C7A.095 Malignant carcinoid tumor of the midgut, unspecified
- C7A.096 Malignant carcinoid tumor of the hindgut, unspecified
- C7A.098 Malignant carcinoid tumors of other sites
- C7A.1 Malignant poorly differentiated neuroendocrine tumors
- C7A.8 Other malignant neuroendocrine tumors
Clinical Terms in This Code Range
Definitions from the National Library of Medicine for conditions coded in the C7A range.
Appendix Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the appendix. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.
Ascending Colon Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the ascending colon. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.
Cecum Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the cecum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.
Descending Colon Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the descending colon. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.
Duodenal Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the duodenum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.
Foregut Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the esophagus, stomach, or duodenum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.
Gastric Neuroendocrine Tumor G3
A well-differentiated, high-grade neuroendocrine neoplasm that arises from the stomach. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.
Hindgut Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the sigmoid colon, descending colon, or rectum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.
Ileal Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the ileum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.
Jejunal Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the jejunum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.
Lung Neuroendocrine Tumor G2
A neuroendocrine tumor of the lung characterized by the presence of 2-10 mitoses per 2 mm2 and/or necrosis (usually punctate).
Midgut Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the jejunum, ileum, proximal colon, or appendix. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.
Neuroendocrine Carcinoma
An aggressive carcinoma composed of malignant cells that exhibit neuroendocrine differentiation. It is classified as small cell or large cell neuroendocrine carcinoma.
Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade epithelial neoplasm with neuroendocrine differentiation. It usually arises from the digestive system, lung, and head and neck.
Rectal Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the rectum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.
Sigmoid Colon Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the sigmoid colon. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.
Thymus Neuroendocrine Tumor G2
A neuroendocrine tumor of the thymus characterized by the presence of 2-10 mitoses per 2 mm2 and/or necrosis (usually punctate).
Transverse Colon Neuroendocrine Tumor G2
A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the transverse colon. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.
About the C7A Code Range
These cancerous tumors include malignant carcinoid tumors and other malignant neuroendocrine tumors.
C7A separates malignant carcinoid tumors (C7A.0), malignant poorly differentiated neuroendocrine tumors (C7A.1), and other malignant neuroendocrine tumors (C7A.8).
Questions About This Page
How many billable codes are in the C7A range?
Of the 28 codes in this range, 23 are billable and valid for claim submission from October 1, 2026 through September 30, 2027. Category header codes group them but cannot be reported on claims.
What does the C7A range classify?
The range classifies malignant neuroendocrine tumors. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.
Related References
Source: CMS FY 2027 ICD-10-CM Tabular List and order file, effective October 1, 2026 through September 30, 2027.
